Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | ETOP NICOLAS: nivolumab, chemotherapy and radiotherapy for NSCLC

Solange Peters • 30 Sep 2019
ESMO 2019
Lung Cancer Non-Small Cell Lung Cancer Nivolumab
NICHOLAS ETOP

Solange Peters, MD, PhD, University Hospital Vaudois, Lausanne, Switzerland, discusses the results of the ETOP NICOLAS trial (NCT02434081). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Solange Peters

2:01
Unanswered questions on immunotherapy for lung cancer
Solange Peters • 11 Sep 2022
3:09
ESMO 2022: Highlights from the Presidential Symposium
Solange Peters • 11 Sep 2022
3:18
Subgroup analysis of PEARLS/KEYNOTE-091: PD-L1 expression and outcomes of pembrolizumab
Solange Peters • 11 Sep 2022
2:42
Aligning the educational resources put out by ESMO
Solange Peters • 30 Sep 2019

Related Videos

3:35
Lung cancer initiation: towards molecular cancer prevention
Charles Swanton • 18 Apr 2024
0:37
STABLE-MATES: sublobar resection vs SAbR in high-risk patients with stage I NSCLC
Clive Peedell • 18 Apr 2024
0:44
BTOG 2024: networking highlights and insights
Clive Peedell • 18 Apr 2024
0:49
Ongoing trials in thoracic radiotherapy: evaluating current role and significance
Thomas Newsom-Davis • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals